AbbVie (ABBV) to Release Earnings on Thursday

AbbVie (NYSE:ABBV) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect AbbVie to post earnings of $3.24 per share and revenue of $14.93 billion for the quarter.

AbbVie Trading Up 1.5%

Shares of ABBV stock opened at $191.29 on Wednesday. The company has a 50-day moving average of $187.81 and a two-hundred day moving average of $189.95. The firm has a market cap of $337.90 billion, a PE ratio of 81.40, a price-to-earnings-growth ratio of 1.24 and a beta of 0.48. AbbVie has a 1-year low of $163.81 and a 1-year high of $218.66. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.43%. AbbVie’s payout ratio is currently 279.15%.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. BNP Paribas upgraded shares of AbbVie to a “hold” rating in a research note on Thursday, May 8th. The Goldman Sachs Group restated a “neutral” rating and issued a $194.00 price objective on shares of AbbVie in a report on Tuesday, April 8th. Bank of America raised their price target on shares of AbbVie to $204.00 and gave the company a “hold” rating in a research report on Monday, June 9th. Finally, Guggenheim upped their price objective on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $211.29.

Institutional Trading of AbbVie

A hedge fund recently raised its stake in AbbVie stock. Revolve Wealth Partners LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 72.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,279 shares of the company’s stock after purchasing an additional 3,064 shares during the period. Revolve Wealth Partners LLC’s holdings in AbbVie were worth $1,294,000 at the end of the most recent reporting period. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.